ECONOMIC IMPACT OF ABOVE-LABEL DOSING WITH BIOLOGICS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1073
https://www.valueinhealthjournal.com/article/S1098-3015(16)01141-4/fulltext
Section Title :
Systemic Disorders/Conditions - Cost Studies
Section Order :
930
First Page :
A250
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01141-4&doi=10.1016/j.jval.2016.03.1073